Free Newsletter

FEATURES >> 15 Top Blockbuster Contenders | 10 Promising Therapeutic Vaccines

Theramex gains â‚¬10M in licensing deal

May 30, 2005 — 7:01pm ET

ALSO NOTED: Repros reports positive data; Sanofi-Aventis would buy if it could; Vertex gains $25M milestone; and much more...
Organon, Schering end male contraceptive deal
Biogen inks $37.5M licensing deal with MondoBiotech
Gene Logic re-examines Organon candidates
Ono halts US trials on acute stroke drug

Tools

Subscribe
Email
Print
Contact Author
Reprint

Merck affiliate Laboratoire Theramex will pocket a €10 million licensing payment from Organon for the marketing rights to its new contraceptive EMM 310066, which has demonstrated efficacy in a Phase II trial. Theramex retains marketing rights in certain companies and also stands to garner milestones and royalties.

- read this story from AFX for more on the deal

SHARE
WITH: